Real-World Evidence: Observational Studies Deserve More Respect In US FDA Framework
Biopharma industry urges agency to open the door wider to use of non-randomized observational studies to support efficacy claims, but insurer Kaiser Permanente calls such studies problematic.
You may also be interested in...
Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will be accepted, US and other regulators are encouraging drug developers to take a chance – and some have taken on the challenge.
The data may be different, but US FDA will consider real-world evidence to add a tissue-agnostic indication, as well as take it away.
US FDA's approach to clinical trial replication project may offer tips for sponsors looking to use real-world evidence to support drug development.